Back

Human Oncogene EWS::FLI1 Functions as a Pioneer Factor in Saccharomyces cerevisiae.

Velazquez, D.; Molnar, C.; Reina, J.; Mora, J.; Gonzalez, C.

2026-04-14 cancer biology
10.1101/2025.10.22.680884 bioRxiv
Show abstract

Ewing sarcoma (EwS) is an aggressive, human-exclusive tumor typically driven by the EWS::FLI1 fusion protein. To assess whether the neomorphic functions of EWS::FLI1 are fundamentally dependent on evolutionarily recent cofactors such as ETS transcription factors (ETS-TFs), Plycomb group (PcG) proteins, CBP/p300, or specific subunits of the BAF complex, we expressed EWS::FLI1 in the model organism Saccharomyces cerevisiae. This minimal system was chosen because several key EWS::FLI 's cofactors possess greatly reduced sequence homology (e.g., BAF) or are lacking altogether (e.g., ETS-TFs, PcG, or CBP/p300). We used co-IP/MS to map the yeast interactome, Chip-Seq to identify gDNA binding sequences, RNA-Seq for global gene expression, and engineered reporters to test conversion of (GGAA) tandem repeats (GGAASat) into neoenhancers. We found that the yeast EWS::FLI1 interactome was more limited and qualitatively distinct from its human counterpart, sharing core machinery (e.g. RNA Polymerase II, FACT) but lacking the BAF/SWI-SNF and spliceosome complexes, and showing strong enrichment for the SAGA chromatin remodeling complex. We also found that EWS::FLI1 binds to hundreds of sites in the yeast genome with a clear preference for putative ETS-TF consensus sequences and (CA) dinucleotide repeats. Yet, EWS::FLI1 expressing cells presented only minimal transcriptional dysregulation, a stark contrast to the extensive changes observed in humans and Drosophila cells. Finally, we found that EWS::FLI1 successfully converted silent GGAASat sequences into active enhancers in yeast. This remarkable result occurs despite the absence of homologs for key human activators, such as CBP/p300, strongly suggesting that EWS::FLI1 can mobilize functionally related, non-homologous pathways to establish neoenhancers at GGAASat sites. Altogether, our results indicate that EWS::FLI1's core ability to drive GGAASat-dependent gene expression is a conserved, ancient property, while GGAASat-independent extensive transcriptome reprogramming is dependent on co-factors and pathways specific to animal cells.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 2%
25.9%
2
Cell Reports
1338 papers in training set
Top 5%
7.2%
3
Nucleic Acids Research
1128 papers in training set
Top 4%
4.9%
4
Developmental Cell
168 papers in training set
Top 4%
4.3%
5
Scientific Reports
3102 papers in training set
Top 27%
4.3%
6
eLife
5422 papers in training set
Top 22%
4.0%
50% of probability mass above
7
EMBO reports
136 papers in training set
Top 0.6%
4.0%
8
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 26%
2.4%
9
Genetics
225 papers in training set
Top 2%
2.4%
10
PLOS Genetics
756 papers in training set
Top 7%
2.1%
11
EMBO Molecular Medicine
85 papers in training set
Top 1%
2.1%
12
The EMBO Journal
267 papers in training set
Top 0.9%
2.1%
13
Cancers
200 papers in training set
Top 3%
1.9%
14
Oncogene
76 papers in training set
Top 0.9%
1.8%
15
iScience
1063 papers in training set
Top 14%
1.7%
16
EMBO Reports
88 papers in training set
Top 0.1%
1.7%
17
Cancer Research
116 papers in training set
Top 2%
1.7%
18
Life Science Alliance
263 papers in training set
Top 0.5%
1.3%
19
Molecular Cell
308 papers in training set
Top 8%
1.3%
20
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 5%
1.3%
21
PLOS Computational Biology
1633 papers in training set
Top 19%
1.2%
22
Molecular and Cellular Biology
40 papers in training set
Top 0.2%
1.2%
23
Genes & Development
90 papers in training set
Top 0.9%
1.0%
24
Communications Biology
886 papers in training set
Top 17%
1.0%
25
Cell Systems
167 papers in training set
Top 11%
0.8%
26
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.8%
27
NAR Cancer
36 papers in training set
Top 0.1%
0.8%
28
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
29
PLOS Biology
408 papers in training set
Top 21%
0.7%
30
Genome Research
409 papers in training set
Top 4%
0.7%